Cite
HARVARD Citation
Liang, D. et al. (2022). Post-marketing safety surveillance of erenumab: new insight from Eudravigilance. Expert opinion on drug safety. 21 (9), pp. 1205-1210. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Liang, D. et al. (2022). Post-marketing safety surveillance of erenumab: new insight from Eudravigilance. Expert opinion on drug safety. 21 (9), pp. 1205-1210. [Online].